Oric Pharmaceuticals, Inc. $ORIC Position Reduced by ArrowMark Colorado Holdings LLC
ArrowMark Colorado Holdings LLC recently reduced its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 14.2% in the third quarter, selling 180,957 shares and retaining over 1 million shares valued at approximately $13.17 million. This move comes as company insiders have also been net sellers, with CEO Jacob Chacko and another insider selling shares totaling over $1.20 million in the past three months. Despite insider selling, analysts maintain a "Moderate Buy" consensus and a price target of $20.20 for ORIC, which is currently trading around $11.90.
How this was made
The 30-second read
Why it matters
While insider and institutional selling can signal caution, the overall analyst sentiment remains moderately bullish, with a price target of $20.20 compared to the current trading price around $11.90.
Market read
The insider activity and stake reduction are noteworthy but do not definitively predict a trend; traders should watch for further insider or institutional moves.
What to watch
Potential upcoming catalysts such as clinical trial results or partnership announcements could offset insider activity concerns
Background
ArrowMark Colorado Holdings LLC reduced its stake in ORIC by 14.2% in Q3, selling approximately 180,957 shares, while insiders including the CEO sold over $1.2 million worth of shares in the past three months.
Ticker impact
Recent insider activity and institutional stake reduction
Potential short-term price decline followed by stabilization
While insider selling and stake reduction may indicate caution, analyst ratings and price targets support a moderate bullish outlook. Lack of significant negative news limits downside risk.
Market effects
Possible minor impact on biotech and life sciences sector sentiment
Limited regional impact due to company-specific news
Low, as news is company-specific and insider activity
Counterpoint
Insider selling may be routine and not indicative of future performance; the company’s fundamentals and analyst support suggest long-term growth potential
Key entities
- Institutional InvestorArrowMark Colorado Holdings LLC
A hedge fund that reduced its stake in ORIC.
- CEOJacob Chacko
Insider who sold shares totaling over $600,000 in recent months.
